Tamayi Bwititi
Family Medicine · Paw Paw, MINPI 1558655464
Payments from drug & device makers
Across 130 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$295
- Pfizer$277
- Lilly USA, LLC$196
- Janssen Products, LP$158
- Novo Nordisk$147
- AstraZeneca$135
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,21595%
- Education$1255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $295 |
| Pfizer | 24 | $277 |
| Lilly USA, LLC | 11 | $196 |
| Janssen Products, LP | 2 | $158 |
| Novo Nordisk | 10 | $147 |
| AstraZeneca | 10 | $135 |
| Gilead | 5 | $110 |
| Boehringer Ingelheim | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| AbbVie | 4 | $72 |
| Viiv Healthcare Company | 4 | $72 |
| Inspire Medical Systems, Inc. | 1 | $58 |
| Amgen | 3 | $52 |
| Astellas Pharma US Inc | 3 | $46 |
| Johnson & Johnson(2 entities) | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| GSK | 3 | $41 |
| Abbott | 2 | $38 |
| Sobi, Inc | 1 | $34 |
| Novartis | 2 | $33 |
| Lundbeck LLC | 1 | $28 |
| Smith+Nephew | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Napo Pharmaceuticals Inc | 1 | $16 |
| Organon | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$2,340 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 123 | $483,105 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 30 | $113,343 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $90,450 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $85,802 |
| MounjaroTirzepatide | 72 | $74,522 |
| TrulicityDulaglutide | 45 | $66,839 |
| EliquisApixaban | 52 | $52,167 |
| PercocetOxycodone Hcl/Acetaminophen | 12 | $52,040 |
| TivicayDolutegravir Sodium | 21 | $45,766 |
| JulucaDolutegravir/Rilpivirine | 13 | $44,746 |
| IsentressRaltegravir Potassium | 23 | $43,415 |
| XareltoRivaroxaban | 30 | $36,289 |
| JardianceEmpagliflozin | 23 | $34,586 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $30,940 |
| JanuviaSitagliptin Phosphate | 27 | $29,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $110 | $514,045137 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Juluca | $72 | $203,85564 claims |
| Lilly USA, LLCMounjaro, Trulicity | $196 | $141,361117 claims |
| MerckIsentress, Januvia, Isentress Hd | $295 | $98,32462 claims |
| Janssen Products, LPSymtuza | $158 | $90,45018 claims |
| PfizerEliquis | $277 | $52,16752 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $41 | $42,83784 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $103 | $40,24935 claims |
| Johnson & JohnsonXarelto | $44 | $36,28930 claims |
| Novo NordiskOzempic | $147 | $20,70023 claims |
| AstraZenecaSymbicort | $135 | $4,70814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Paw Paw
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.